Novartis Receives FDA Approval for Rhapsido (remibrutinib) for Chronic Spontaneous Urticaria

Novartis (NYSE:NVS) is one of the best growth stocks to buy now. On September 30, Novartis announced the US FDA approval of its drug, Rhapsido (remibrutinib). This oral pill is approved for use in adult patients with chronic spontaneous urticaria/CSU whose symptoms persist despite treatment with H1 antihistamines.

Rhapsido is a pill taken twice daily and is significant because it is the first oral, targeted Bruton’s tyrosine kinase inhibitor/BTKi to be FDA-approved for CSU, offering a non-injectable option that does not require routine lab monitoring. Rhapsido targets the core mechanism of CSU, which is a mast cell-driven condition thought to be caused by immune dysregulation.

The drug works by blocking the activity of the BTK protein in immune cells, which in turn helps to inhibit the release of histamine and other proinflammatory mediators. This is a crucial development for the 1.7 million people in the US living with CSU, as over half of them remain symptomatic even with increased doses of standard antihistamines, and fewer than 20% of eligible patients currently receive existing injectable treatments.

Novartis (NYSE:NVS) researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.

While we acknowledge the potential of NVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.